No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Etonogestrel (vaginal ring)
Quality of Evidence:
Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Emtricitabine and tenofovir-DF do not interact with this metabolic pathway. No clinically significant drug interactions were observed when tenofovir-DF was coadministered with a COC containing ethinylestradiol/norgestimate.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking